MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- SANOFI INDIA LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Aventis Pharma Quarterly Results (HOCM)
Here are the latest quarterly results of Aventis Pharma. For more details, see the Aventis Pharma financial fact sheet and Aventis Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
Aventis Pharma Quarterly Results
| No. of Mths Qtr. Ending |
3
Sep-17 |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
3
Sep-18 |
3
Dec-18 |
3
Mar-19 |
3
Jun-19 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 6,675 | 6,704 | 6,177 | 6,836 | 7,438 | 7,264 | 7,173 | 7,479 | |
| Other income | Rs m | 208 | 182 | 226 | 208 | 262 | 201 | 230 | 234 | |
| Turnover | Rs m | 6,883 | 6,886 | 6,403 | 7,044 | 7,700 | 7,465 | 7,403 | 7,713 | |
| Expenses | Rs m | 4,838 | 5,360 | 4,833 | 5,191 | 5,565 | 5,891 | 5,635 | 5,901 | |
| Gross profit | Rs m | 1,837 | 1,344 | 1,344 | 1,645 | 1,873 | 1,373 | 1,538 | 1,578 | |
| Depreciation | Rs m | 257 | 257 | 254 | 254 | 260 | 259 | 261 | 260 | |
| Interest | Rs m | 0 | 11 | 0 | 0 | 0 | 7 | 0 | 0 | |
| Profit before tax | Rs m | 1,788 | 1,258 | 1,316 | 1,599 | 1,875 | 1,308 | 1,507 | 1,552 | |
| Tax | Rs m | 625 | 498 | 491 | 603 | 683 | 515 | 578 | 578 | |
| Profit after tax | Rs m | 1,163 | 760 | 825 | 996 | 1,192 | 793 | 929 | 974 | |
| Gross profit margin | % | 27.5 | 20.0 | 21.8 | 24.1 | 25.2 | 18.9 | 21.4 | 21.1 | |
| Effective tax rate | % | 35.0 | 39.6 | 37.3 | 37.7 | 36.4 | 39.4 | 38.4 | 37.2 | |
| Net profit margin | % | 17.4 | 11.3 | 13.4 | 14.6 | 16.0 | 10.9 | 13.0 | 13.0 | |
| Diluted EPS | Rs | 50.5 | 33.0 | 35.8 | 43.2 | 51.8 | 34.4 | 40.3 | 42.3 | |
| Diluted EPS (TTM) | Rs | 143.6 | 141.6 | 151.3 | 162.6 | 163.8 | 165.3 | 169.8 | 168.8 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Aventis Pharma 1QFY20 Result Performance Review
More Pharmaceuticals Company Quarterly Results: ELDER PHARMA CIPLA AJANTA PHARMA GSK PHARMA DISHMAN PHARMA
Compare SANOFI INDIA With: ELDER PHARMA CIPLA AJANTA PHARMA GSK PHARMA DISHMAN PHARMA
Compare SANOFI INDIA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)
Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.
Views on news
SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)
Jul 31, 2019 | Updated on Jul 31, 2019For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)
May 8, 2019 | Updated on May 8, 2019For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)
Apr 16, 2019 | Updated on Apr 16, 2019Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints? (Profit Hunter)
Nov 7, 2019Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?
Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks (The 5 Minute Wrapup)
Nov 8, 2019Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.
These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound (Profit Hunter)
Nov 5, 2019How to avoid the most common investing mistake and make the most of the smallcap rebound.
The Top Stocks for 2020 Pass This Most Critical Metric (The 5 Minute Wrapup)
Nov 5, 2019Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.
What to Buy at Sensex 40,000 (The 5 Minute Wrapup)
Nov 4, 2019Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?
More|
| |
SANOFI INDIA SHARE PRICE
Nov 15, 2019 (Close)
TRACK SANOFI INDIA
- Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SANOFI INDIA
SANOFI INDIA 5-YR ANALYSIS
COMPARE SANOFI INDIA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.